Chugai Pharmaceutical
Roche-group biopharmaceutical company originating and developing biologics across hematology, oncology, immunology, and neuroscience.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Bispecific monoclonal antibody
satralizumabIL-6 receptor-directed monoclonal antibody
tocilizumabIL-6 receptor-directed monoclonal antibody
Selected active clinical trials
Phase 2 · Recruiting · Celiac Disease
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)Phase 1 · Recruiting · Antiphospholipid Syndrome (APS)
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid TumorsPhase 1 · Recruiting · Solid Tumor
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERPhase 1 · Recruiting · Extensive Stage Small Cell Lung Cancer
Study of AUBE00 in Patients With Solid TumorsPhase 1 · Recruiting · Solid Tumors
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerPhase 1 · Recruiting · ALK Positive Non-small Cell Lung Cancer
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/chugai-pharmaceutical/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.